Answers are grounded in this paper and cite their sources.
Serrano et al. recently reported that prolonged treatment with high doses of the DNA hypomethylating agent 5-AZA-2′-deoxycitydine (5-AZA-CdR) induced de novo expression of the mRNA encoded by HLA-A, -B and -C loci in the HLA class I-negative melanoma cell line MSR3-mel. 1 Combined treatment with 5-AZA-CdR and interferon (IFN)-γ resulted in the expression of HLA-A and -B proteins on the cell membrane of MSR3-mel melanoma cells and induced higher levels of HLA-B antigens. Furthermore, the authors demonstrated that exposure of MSR3-mel melanoma cells to 5-AZA-CdR, IFN-γ and tumor necrosis (TNF)-α resulted in their recognition by HLA-A and -B restricted tumor-specific cytotoxic T cells (CTL). In light of these findings, the authors suggested that DNA hypermethylation is a new molecular mechanism generating complete loss of HLA class I antigens expression in human melanomas and concluded that pharmacologic modulation of DNA methylation represents a possible intervention for cancer treatment, which, however, is limited by the high toxicity of available DNA hypomethylating drugs. We have shown that 5-AZA-CdR significantly (p < 0.05) and persistently upregulates the constitutive expression of HLA class I antigens and of HLA-A1 and -A2 allospecificities on primary cultures of metastatic melanoma cells. 2 These findings, and the concomitant de novo expression or upregulation of Cancer Testis Antigens (CTA) by 5-AZA-CdR,2, 3 led us to propose for its perspective clinical usefulness to implement new therapeutic strategies in melanoma patients.2, 3 Nevertheless, we found that 5-AZA-CdR did not induce de novo expression of the HLA-A2 allospecificity on HLA class I antigens-positive but HLA-A2-negative melanoma cultures (data not shown). These evidences suggested to us that DNA hypermethylation does not represent a mechanism utilized by melanoma cells to turn off their expression of HLA class I antigens. The data generated with MSR3-mel melanoma cells, 1 which clearly point to a different conclusion, prompted us to extend our preliminary findings. To this end, primary cultures of metastatic melanoma cells from patients with no history of chemotherapy or immunotherapy, 4 of which showed complete loss of HLA class I antigens and 4 with selective loss of the HLA-A2 allospecificity (Table I), were pulsed 4 times with 1 μM 5-AZA-CdR every 12 hr and further cultured as previously described.2, 3 5-AZA-CdR constantly failed to induce de novo expression of HLA class I antigens and of the HLA-A2 allospecificity on investigated melanoma cells (Table I); however, as expected, it upregulated their baseline expression (Table I). The DNA hypomethylating effect of 5-AZA-CdR was confirmed by the induction or by the upregulation of the expression of the CTA MAGE-1, -2, -3, GAGE 1-2, NY-ESO-1 and SSX 1–5 in melanoma cultures studied and by a significant inhibition of cellular replication (data not shown). In spite of these experimental evidences, we reasoned that higher concentrations of 5-AZA-CdR and/or longer exposure to the demethylating agent could restore the deficient expression of HLA class I molecules. However, in our present and previous experience with more than 40 different melanoma cultures, we were invariably unable to increase the concentrations of 5-AZA-CdR and/or to prolong the length of treatment over 4 days, as this resulted in complete destruction of neoplastic cells. Therefore, according to the culture conditions described by Serrano et al., MSR3-mel likely represents a melanoma cell line with an exquisite resistance to the growth inhibitory and cytotoxic activity of 5-AZA-CdR. 4 We have also shown that opposite to IFN-γ, treatment with 5-AZA-CdR upregulates the expression of HLA-A and -B antigens to a similar extent on melanoma cells. 5 Thus, it will be interesting to dissect in depth the relative contribution of 5-AZA-CdR, IFN-γ and/or TNF-α in the reported recognition of MSR3-mel melanoma cells by effector CTL. In fact, the absolute requirement of all 3 therapeutic components to achieve the observed functional results would add great complexity to a foreseeable therapeutic schema, while further increasing the toxicity of DNA hypomethylating agents used alone. Altogether, the experimental evidences available strongly suggest that DNA hypermethylation is a molecular mechanism that melanoma cells consistently utilize to downregulate but not to switch off their expression of HLA class I antigens; in this respect, MSR3-mel melanoma cells very likely represent the exception rather than the rule. Furthermore, we would disagree with the assertion by Serrano et al. that the high toxicity of available DNA hypomethylating agents makes their use problematic in the clinical setting. In fact, the concomitant upregulation of HLA class I antigens and of costimulatory molecules, together with the simultaneous induction/upregulation of the expression of distinct CTA observed after exposure to much less toxic doses of 5-AZA-CdR, 3, 4 results in enhanced recognition of neoplastic cells by CTA-restricted CTL (data not shown). Thus, we would rather conclude that 5-AZA-CdR represents a very promising pharmacologic agent that is worth considering when setting up new combined chemo-immunotherapeutic strategies in advanced melanoma patients. Yours sincerely, Ester Fonsatti*, Luca Sigalotti*, Sandra Coral*, Francesca Colizzi*, Maresa Altomonte*, Michele Maio*, * Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
No takes yet. Share an insight, caveat, or question.
Fonsatti et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: